Status:
COMPLETED
Borderzone Sampling
Lead Sponsor:
Maastricht University Medical Center
Conditions:
High Grade Glioma
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
On regular (diagnostic) MRI images brain tumors can show "contrast enhancement": uptake of an intravenously administered contrast agent can cause an enhancement pattern that is seen as a white area on...
Eligibility Criteria
Inclusion
- supratentorial brain tumor, on contrast enhanced MRI suspect for a high grade glioma
- indication for resection of the tumor
- age ≥ 18 years
- WHO Performance Scale ≤ 2
- ASA class ≤ 3
- good knowledge of the Dutch language
- informed consent
Exclusion
- recurrent tumor
- multiple tumor localizations
- prior radiotherapy on the skull
- prior chemotherapy
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00780819
Start Date
October 1 2008
End Date
December 1 2012
Last Update
May 14 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University Medical Center
Maastricht, Limburg, Netherlands, 6202 AZ